September 17, 2019 News by Ana Pena PhD #ECTRIMS2019 ā Ofatumumab Superior to Aubagio in Lowering Relapse Rates and Lesions, Data Show Monthly under-the-skin injections of ofatumumab are superior to AubagioĀ (teriflunomide) to treat relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), leading to over 50% reduction in relapse rates, and more than a 90% reduction in active brain lesions, compared with Aubagio, results from ASCLEPIOS I…
September 16, 2019 News by Ana Pena PhD #ECTRIMS2019 – Mayzent Reduces Risk of SPMS Patients Becoming Wheelchair Bound, Data Show Mayzent (siponimod) reduces the risk of people with secondary progressive multiple sclerosis (SPMS) becoming dependent on a wheelchair, a new analysis of the EXPAND study shows. These findings further corroborate prior trial data demonstrating that Mayzent use delays disability progression and cognitive decline in SPMS patients. The results…
September 13, 2019 News by Ana Pena PhD #ECTRIMS2019 – Mesenchymal Stem Cell Transplants Safe and Help Stop Progressive MS, Trial Data Show Transplanting mesenchymal stem cells (MSCs) is safe and can delay disease progression in people with active, progressive multiple sclerosis (MS), according to results from a single-center clinical trial conducted in Israel. Six months after the transplant, a considerable proportion of patients showed no signs of disease activity, compared to…
September 13, 2019 News by Ana Pena PhD #ECTRIMS2019 – Longer DMT Use and Female Sex Seen to Protect Against SPMS Conversion Women with multiple sclerosis (MS), and people who stay in a relapsing stage or use disease-modifying therapies (DMTs) for longer periods are less likely to transition to secondary progressive multiple sclerosis (SPMS) than others, according to a study based on the Italian MS registry. But patients whose…
September 10, 2019 News by Steve Bryson, PhD SPMS Triggers and Treatments Among Focus of Expert Panel in Video Series by AJMC Multiple sclerosis (MS) experts discuss disease causes and current treatment options in a new video series released by the multimedia and peer-reviewed science journal,Ā The American Journal of Managed Care (AJMC).Ā The free and online video series is part…
July 22, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Ibudilast Trial for Inactive SPMS, PPMS Brain Cells in Space, MS and Cancer Risk Phase 3 Trial of Ibudilast Planned for SPMS Patients with Inactive Disease, MediciNova Says Though medications are approved in the U.S. to treat primary progressive multiple sclerosis and active secondary progressive MS (SPMS), no disease-modifying treatments are approved to treat the nonactive form of SPMS. This trial aims…
July 17, 2019 News by Ana Pena PhD Phase 3 Trial of Ibudilast Planned for SPMS Patients with Inactive Disease, MediciNova Says A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses, or those whose disease is not active, MediciNovaĀ announced. Data from this single Phase 3 study may be used to request…
July 11, 2019 Columns by Jennifer (Jenn) Powell My Independence Day: Reinventing Ability with SPMS The glow of the fireworks bathes the surrounding trees. A kaleidoscope of blue, yellow, and red illuminates the night sky. It is a day of picnics, parades, and pyrotechnics. It is the Fourth of July, when Americans celebrate gaining their independence from Great Britain. I can relate to celebrating…
July 8, 2019 News by Jose Marques Lopes, PhD Mayzent Boosts Cognitive Processing Speed in SPMS Patients, Phase 3 Trial Data Show Treatment with Mayzent (siponimod) led to significant improvement in cognitive processing speed in patients with secondary progressive multiple sclerosis (SPMS), according to updated results of a Phase 3 trial. Novartisā findings, presented at the European Academy of Neurology (EAN) congressĀ that ran June 29āJuly 2 in Oslo,…
July 2, 2019 News by Ana Pena PhD Neurologists Prefer Mayzent for SPMS and RRMS, But Mavenclad Could Be ‘Ideal’ First Switch, Report Suggests While neurologists favor Novartis‘ Mayzent (siponimod) for people with active secondary progressive multiple sclerosis (SPMS) and transitioning relapsing-remitting MS (RRMS), EMD Serono‘s Mavenclad (cladribine) could serve as a first option for patients with RRMS who failed initial therapy, Spherix Global Insights says in its…
May 22, 2019 News by Joana Carvalho, PhD Simvastatin, Common Statin, Treats SPMS in Ways Distinct from Cholesterol, Study Suggests Simvastatin, a widely prescribed statin that works to lower cholesterolĀ levels, may slow brain atrophy and disease progression in people with secondary progressive multiple sclerosis (SPMS) for reasons unrelated to changes in blood cholesterol, a new analysis of a Phase 2 clinical trial reports. These findings are in…
May 16, 2019 Columns by Jennifer (Jenn) Powell Trading Teacups for Buckets: Keeping Dreams Alive with SPMS They say that the only certainties in life are death and taxes. While I agree with these two, a third inevitability is capitulation. Why do we have theme parks when we have lives? We have highs and lows and homeostasis in-between. Just when you think it is safe to exhale,…
May 9, 2019 Columns by Jennifer (Jenn) Powell Perception Over Pain: Making a Mental Shift with SPMS I am a positive person with not-so-positive moments. These moments don’t quantify my essence. Nevertheless, they sure try. I work hard to keep the negativity at bay, but I don’t always succeed. As I write, I’m overcome with pain and fatigue. This is not the exception but the…
May 9, 2019 News by Jose Marques Lopes, PhD #AANAM – Scoring Tool Helps Identify Patients with RRMS or Transitioning to SPMS, Study Reports A newly developed scoring tool enables better identification of patients with relapsing-remitting multiple sclerosis (RRMS) as well as those transitioning or already diagnosed with secondary progressive MSĀ (SPMS). The research about that finding, āValidation of the Scoring Algorithm for a Novel Integrative Secondary Progressive Multiple Sclerosis (SPMS) Screening Tool,ā…
May 9, 2019 News by Jose Marques Lopes, PhD #AANAM – Mayzent Improves Cognitive Processing Speed in SPMS Patients, Trial Results Show Treatment with Mayzent (siponimod) provided sustained improvements and prevented deterioration of cognitive processing speed in patients with secondary progressive multiple sclerosis (SPMS), regardless of their cognitive function prior to therapy, according to results of a Phase 3 clinical trial. The data were presented at the recent 2019Ā American…
May 7, 2019 News by Jose Marques Lopes, PhD #AANAM ā Tysabri Lowers Serum Neurofilament Light Levels in SPMS Patients, Phase 3 Trial Finds Treatment with TysabriĀ (natalizumab) lowers the levels of the biomarker serum neurofilament light chain (sNfL) in patients with secondary progressive multiple sclerosisĀ (SPMS), according to data from a Phase 3 trial. Findings also revealed that higher levels of sNfL correlated with MS lesions and disease activity prior to starting the…
April 11, 2019 Columns by Jennifer (Jenn) Powell The Unlikely Warrior: Finding Purpose with SPMS I am balancing my laptop on one pillow and a leg brace. I have myriad MS-related health issues; alas, this is not among them. AfterĀ meniscus surgery, aggressive arthritis, and a loss of cartilage, I’m facingĀ knee replacement. Due to a busy schedule and the sustaining effects ofĀ RituxanĀ (rituximab),…
April 10, 2019 News by Jose Marques Lopes, PhD Different Ways of Working Tailor Mayzent for Early SPMS Patients, Novartis Says The effectiveness of MayzentĀ (siponimod) in both the brain and the body make it an oral therapy tailored for people with early secondary progressive multiple sclerosisĀ (SPMS), according to Dan Bar-Zohar, MD, top executive with Novartis, the treatmentās developer. Mayzent was recentlyĀ approvedĀ by the U.S. Food and Drug Administration…